We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 22, 2022

CTS5 Risk Model vs 21-Gene Recurrence Score Assay and the Development of a Novel Nomogram for Predicting Survival in HR+ Breast Cancer

The Breast

 

Additional Info

The Breast
Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction
Breast 2022 Jun 01;63(xx)61-70, C Wang, Y Xu, Y Lin, Y Zhou, F Mao, X Zhang, S Shen, Y Zhang, Q Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading